![]() ![]() ![]() Our revenues for the nine months ended Septemhave already surpassed the entire year 2015 revenues as a result of increased collections from our FDA approved plasma collection facilities. Additionally, we continue to refine and focus our business operations on necessary activities and continue to see growth in our ADMA BioCenters business unit, through expanding upon our customer base for the purchase of normal source plasma. We remain committed to bring RI-002 to market for Primary Immune Deficiency Disease (PIDD) patients and other future patient populations, which might benefit from our novel immune globulin. “RI-002 continues to be discussed in multiple articles and abstracts published in peer-reviewed journals as well as presentations at medical conferences about the use of our investigational product candidate in various immune compromised patient populations. We expect to provide a timeline for our Biologics License Application (BLA) resubmission for RI-002 after we receive feedback regarding previous submissions, from the FDA,” stated Adam Grossman, President and CEO of ADMA Biologics, Inc. Food and Drug Administration (FDA) in the third quarter for RI-002. “Together with our third-party manufacturers and vendors, ADMA continues to make progress in finding solutions to address inspection and compliance issues identified in the Complete Response Letter (CRL) received from the U.S. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases, today announced its financial results for the quarter ended September 30, 2016. 10, 2016 (GLOBE NEWSWIRE) - ADMA Biologics, Inc. Contract Manufacturing and Aseptic Fill-Finish.About Primary Immunodeficiency Disease (PI). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |